Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Short Interest Update

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 21,160 shares, a drop of 35.1% from the June 15th total of 32,585 shares. Based on an average daily trading volume, of 2 shares, the days-to-cover ratio is presently 10,580.0 days.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Towa Pharmaceutical to an “overweight” rating in a research note on Friday, June 12th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Towa Pharmaceutical Price Performance

Shares of OTCMKTS TWAPF opened at $26.00 on Friday. Towa Pharmaceutical has a 1 year low of $25.71 and a 1 year high of $26.00. The firm has a fifty day moving average price of $25.44 and a 200-day moving average price of $25.37.

About Towa Pharmaceutical

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.